Trial Profile

An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 05 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Leronlimab (Primary)
Indications HIV-1 infections
Focus Adverse reactions; Therapeutic Use
Sponsors CytoDyn

Most Recent Events

29 Feb 2024 According to a CytoDyn media release, the clinical hold on leronlimab has been lifted by the FDA.
01 Feb 2024 According to a CytoDyn media release, company announced that it has submitted its revised HIV clinical trial protocol to the FDA and company believes that this submission will lead to the removal of the clinical hold currently in effect.
30 Mar 2022 Status changed from active, no longer recruiting to suspended, according to a CytoDyn media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com